Physician profile
Ehsan Chitsaz
NPI 1285993576
$1,996.50
in general payments reported to CMS, 2019-2025
21 companies · $1,329 in 2025
The $1,329 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2021: $11.43 · 2022: $207 · 2023: $14.11 · 2024: $333 · 2025: $1,329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,676.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $449.15 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $400.82 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $185.53 | 2022-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $160.09 | 2025 | Tremfya, Stelara, Simponi Aria |
| Olympus America INC. | $137.85 | 2025 | Olympus, Hanarostent Esophagus Tts(Ccc), Visiglide |
| Qol Medical, LLC | $118.13 | 2025 | Sucraid |
| Regeneron Healthcare Solutions, INC. | $99.73 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $87.99 | 2023-2025 | Xifaxan |
| Gilead Sciences, INC. | $56.17 | 2025 | |
| Teleflex LLC | $54.52 | 2022 | |
| Pfizer INC. | $54.21 | 2025 | |
| Tersera Therapeutics LLC | $33.76 | 2025 | Xermelo |
| Nestle Healthcare Nutrition INC. | $26.04 | 2022 | |
| Recordati_rare_diseases_inc. | $22.88 | 2025 | Panhematin |
| Phathom Pharmaceuticals, INC. | $20.84 | 2024-2025 | Voquezna |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $16.43 | 2025 | Wegovy |
| Organon LLC | $16.32 | 2025 | Renflexis, Hadlima |
| Braintree Laboratories, INC. | $16.16 | 2025 | Suflave, Sutab |
| Evoke Pharma, INC. | $14.37 | 2025 | |
| Intercept Pharmaceuticals, INC. | $13.81 | 2025 | |
| Merit Medical Systems INC | $11.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ehsan Chitsaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.